PTGS1 and Alzheimer disease: Our study demonstrated that the EP2 receptor functions as a crucial downstream factor in COX-1-mediated neuroinflammatory processes and presents another promising pharmacological target for mitigating the pathological effects associated with COX-1 activity in AD patients.